HD-OPM Archive
Topics › Plaque, CAC & CT angiography

Pioglitazone slowed coronary plaque progression and shrank necrotic core in diabetics

Gokhan Can · Jan 14, 2025 · ♥ 17 reactions · 27 comments · original Facebook post
Plaque, CAC & CT angiographyInsulin resistance & diabetesInflammation & CRP
AI summary & key facts

Data-rich overview of pioglitazone's effects on plaque. In PERISCOPE (543 type 2 diabetes patients with CAD, 18 months, IVUS) pioglitazone lowered percent atheroma volume while glimepiride raised it. A smaller trial (Ogasawara 2009) found reduced necrotic core and higher adiponectin, suggesting benefit via reduced inflammation.

Pioglitazone for Atherosclerotic Plaque

Below is a data-rich overview of how pioglitazone (PPARγ agonist) affects atherosclerotic plaque in humans. References to specific studies and key numerical results are provided, along with practical considerations for patients.

Overview: Pioglitazone and Atherosclerotic Plaque

Pioglitazone, used primarily to improve insulin sensitivity in type 2 diabetes (T2D), has also been shown in multiple clinical trials to reduce coronary plaque volume, shift plaque composition toward a more stable phenotype, and decrease vascular inflammation. Unlike statins, which strongly reduce LDL and stabilize plaque primarily through lipid-lowering, pioglitazone’s anti-atherogenic actions appear more closely tied to reductions in inflammation, increases in adiponectin, and improved insulin sensitivity.

Major Findings From Key Studies

1) PERISCOPE Trial (Nissen et al., 2008)

2) Ogasawara et al., 2009

Why It Matters

3) Christoph et al. (2015)

4) Nakayama et al., 2010

5) Yang et al., 2012

6) Clementi et al., 2009

Despite the contradictory finding on necrotic core, overall volume decreased. Some authors theorize that as the plaque regresses, it may reorganize, transiently altering the proportion of tissue components.

7) Pioglitazone and Coronary Inflammation by 18F-FDG PET/CT

Common Themes & Mechanisms

  1. Plaque Regression
  1. Plaque Composition Stabilization
  1. Anti-Inflammatory Action
  1. Adiponectin Increase
  1. Beyond Glucose Lowering

What Should a Patient Do?

  1. Continue Standard Cardiovascular Risk Management
  1. Discuss Pioglitazone’s Risks and Benefits With Your Clinician
  1. Address Dosing and Monitoring
  1. Maintain Lifestyle Measures

Bottom Line

Multiple clinical trials using intravascular imaging—IVUS, VH-IVUS, and FDG-PET/CT—consistently demonstrate that pioglitazone can reduce coronary plaque volume, decrease necrotic core components, and lower vascular inflammation, independent of its glucose-lowering effect. By raising adiponectin and suppressing inflammatory pathways, pioglitazone is associated with stabilization or regression of atherosclerotic plaques in both diabetic and non-diabetic patients.

While these findings are highly encouraging, it is essential that patients considering pioglitazone:

In short, pioglitazone offers a valuable option to enhance plaque stability and potentially reduce cardiovascular events, but should always be integrated with comprehensive cardiovascular risk management.

References

docs.google.comGoogle DocPioglitazone for Atherosclerotic Plaque Below is a data-rich overview of how pioglitazone (a peroxisome proliferator–activated receptor γ [PPARγ] agonist) affects atherosclerotic plaque in humans. References to specific studies and key numerical results are provided, along with practical conside...docs.google.com

Research cited

#pioglitazone#plaque#inflammation#adiponectin#ivus#glucose#insulin#hscrp
← newer: Pomegranate juice and heart health: CIMT, blood pressure andolder: Exercise lowers coronary plaque burden; HIIT cut atheroma vo →